Q2 FY2026 EarningsQ2 FY26 results significantly missed consensus on profitability metrics, primarily due to a massive non-cash warrant liability charge. Net loss of $74.8M was 464% wider than the $13.3M expected, resulting in a GAAP EPS of -$0.80 vs. -$0.16 consensus. Despite the earnings miss, the company bolstered its balance sheet through a $354M private placement, ending the quarter with $187.3M in cash. Strategic focus remains on the Q4 2026 NDA resubmission and H1 2027 potential FDA approval.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Achieve Life Sciences(ACHV) the EBIT is -18.39 M (-46.4%), Miss estimate;the EPS is -0.8 (-116.2%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B46.40%
-0.01B7.49%
-0.00B38.91%
EPSMiss expectations
-0.8116.22%
-0.164655.53%
-0.6354171.75%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf